Registering a new drug in South Korea typically takes 12 to 18 months. The process involves submitting clinical, preclinical, and manufacturing data to the Ministry of Food and Drug Safety (MFDS) for review. Expedited pathways may shorten timelines for priority drugs, such as treatments for rare diseases or serious conditions.
